CoChat

Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer

Open access
Sadeghi, Mohammad Mojtaba, Salama, Mohamed F., Hannun, Yusuf A. · 2021 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Abstract

Driver-directed therapeutics have revolutionized cancer treatment, presenting similar or better efficacy compared to traditional chemotherapy and substantially improving quality of life. Despite significant advances, targeted therapy is greatly limited by resistance acquisition, which emerges in nearly all patients receiving treatment. As a result, identifying the molecular modulators of resistance is of great interest. Recent work has implicated protein kinase C (PKC) isozymes as mediators of drug resistance in non-small cell lung cancer (NSCLC). Importantly, previous findings on PKC have implicated this family of enzymes in both tumor-promotive and tumor-suppressive biology in various tissues. Here, we review the biological role of PKC isozymes in NSCLC through extensive analysis of cell-line-based studies to better understand the rationale for PKC inhibition. PKC isoforms α, ε, η, ι, ζ upregulation has been reported in lung cancer, and overexpression correlates with worse prognosis in NSCLC patients. Most importantly, PKC isozymes have been established as mediators of resistance to tyrosine kinase inhibitors in NSCLC. Unfortunately, however, PKC-directed therapeutics have yielded unsatisfactory results, likely due to a lack of specific evaluation for PKC. To achieve satisfactory results in clinical trials, predictive biomarkers of PKC activity must be established and screened for prior to patient enrollment. Furthermore, tandem inhibition of PKC and molecular drivers may be a potential therapeutic strategy to prevent the emergence of resistance in NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22115527

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 An overview of lung cancer histology and driver mutations in adenocarcinoma patients.
Figure 1 An overview of lung cancer histology and driver mutations in adenocarcinoma patients.CC BY · PubMed Central
Figure 2 A schematic representation of PKC subfamily structural domains. Distinct PKC isozymes are categorized into classical, novel, or atypical PKCs based on N-terminal regulatory domain structure and have conserved C1-4 domains. Classical PKC α, β1, β2, γ are activated by DAG and calcium through binding with C1A-C1B and C2 domain, respectively. Novel PKC isoforms δ, ε, η, θ are DAG dependent but calcium independent for their activation, as the C2-like domain cannot bind calcium. Atypical PKC ζ, ι do not respond to calcium or DAG. All PKC isozymes have a pseudosubstrate (PS) domain involved in kinase auto-inhibition. The C-terminal catalytic domain is highly homologous between all the PKC isozymes and consists of an ATP binding C3 domain and a C4 kinase domain.
Figure 2 A schematic representation of PKC subfamily structural domains. Distinct PKC isozymes are categorized into classical, novel, or atypical PKCs based on N-terminal regulatory domain structure and have conserved C1-4 domains. Classical PKC α, β1, β2, γ are activated by DAG and calcium through binding with C1A-C1B and C2 domain, respectively. Novel PKC isoforms δ, ε, η, θ are DAG dependent but calcium independent for their activation, as the C2-like domain cannot bind calcium. Atypical PKC ζ, ι do not respond to calcium or DAG. All PKC isozymes have a pseudosubstrate (PS) domain involved in kinase auto-inhibition. The C-terminal catalytic domain is highly homologous between all the PKC isozymes and consists of an ATP binding C3 domain and a C4 kinase domain.CC BY · PubMed Central
Figure 3 A scheme defining the biological roles of PKC in NSCLC.
Figure 3 A scheme defining the biological roles of PKC in NSCLC.CC BY · PubMed Central
Figure 4 A scheme outlining PKC-mediated drug resistance in EGFR and KRAS mutant NSCLC.
Figure 4 A scheme outlining PKC-mediated drug resistance in EGFR and KRAS mutant NSCLC.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 116 references

Cited by

See all 34

Metadata

Authors
Sadeghi, M. M., Salama, M. F., & Hannun, Y. A.
Affiliations
  • Department of Biochemistry, Molecular and Cellular Biology, Stony Brook University, Stony Brook, NY 11794, USA
  • Mansoura University (EG)
  • Stony Brook University Hospital (US)
Corresponding author
Hannun, Yusuf A.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-05-24
Volume
22
Issue
11
Pages
5527
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3164693058
Cited by
31
References
119
Citations by year
2026: 4 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 4 · 2021: 1
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Department of Veterans Affairs (I01 BX004621)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
protein kinase C, non-small cell lung cancer, drug resistance, tyrosine kinase inhibitors, PKC isoforms, predictive biomarkers, combination therapy, targeted therapy
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Lung Neoplasms, Prognosis, Protein Kinase C, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Protein Isoforms, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.3390/ijms22115527
The paper
Sadeghi, M. M., Salama, M. F., & Hannun, Y. A. (2021). Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22115527

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.